MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
April 19, 2024 at 10:03 am EDT
Share
EQS Voting Rights Announcement: MorphoSys AG
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
19.04.2024 / 16:02 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
MorphoSys AG
Street:
Semmelweisstr. 7
Postal code:
82152
City:
Planegg Germany
Legal Entity Identifier (LEI):
529900493806K77LRE72
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Legal entity: JPMorgan Chase & Co. City of registered office, country: Wilmington, Delaware, United States of America (USA)
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
J.P. Morgan Securities plc; J.P. Morgan Securities LLC
5. Date on which threshold was crossed or reached:
16 Apr 2024
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
7.48 %
1.22 %
8.70 %
37716423
Previous notification
8.99 %
1.67 %
10.66 %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE0006632003
0
2821618
0.00 %
7.48 %
Total
2821618
7.48 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
Convertible bonds
16/10/2025
16/10/2025
Physical
373218
0.99 %
Cash-settled Call Options
12/01/2026-02/01/2099
Anytime
Cash
3603
0.01 %
Physically-settled Put Options
23/05/2024
23/05/2024
Physical
3125
0.01 %
Equity Swap
29/11/2024 -27/11/2030
29/11/2024 -27/11/2030
Cash
79398
0.21 %
Total
459344
1.22 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
JPMorgan Chase & Co.
%
%
%
JPMorgan Chase Bank, National Association
%
%
%
J.P. Morgan International Finance Limited
%
%
%
J.P. Morgan Capital Holdings Limited
%
%
%
J.P. Morgan Securities plc
4.28 %
%
5.49 %
-
%
%
%
JPMorgan Chase & Co.
%
%
%
JPMorgan Chase Holdings LLC
%
%
%
J.P. Morgan Broker-Dealer Holdings Inc.
%
%
%
J.P. Morgan Securities LLC
3.20 %
%
%
-
%
%
%
JPMorgan Chase & Co.
%
%
%
JPMorgan Chase Bank, National Association
%
%
%
J.P. Morgan International Finance Limited
%
%
%
J.P. Morgan Structured Products B.V.
%
%
%
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
Date
18 Apr 2024
19.04.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution